NFA
ACRS icon

Nationwide Fund Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Nationwide Fund Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,732
Closed -$329K – 33
2017
Q3 		$329K Buy
12,732
+1,309
+11% +$35.1K ﹤0.01% 2392
2017
Q2 		$310K Buy
11,423
+4,796
+72% +$130K ﹤0.01% 2430
2017
Q1 		$198K Buy
6,627
+510
+8% +$14.7K ﹤0.01% 2596
2016
Q4 		$166K Buy
6,117
+370
+6% +$9.43K ﹤0.01% 2690
2016
Q3 		$147K Hold
5,747
– – ﹤0.01% 2769
2016
Q2 		$106K Buy
5,747
+1,838
+47% +$36.4K ﹤0.01% 2885
2016
Q1 		$74K Buy
3,909
+491
+14% +$9.38K ﹤0.01% 2902
2015
Q4 		$92K Buy
+3,418
New +$66.6K ﹤0.01% 2876

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Nationwide Fund Advisors's ACRS Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Aclaris Therapeutics (ACRS) in Q4 2017, closing a stake of 12,732 shares — an estimated $329K sold.

Nationwide Fund Advisors first reported a position in ACRS in Q4 2015 and held it in 8 quarters. The position peaked at $329K in Q3 2017. 102 funds tracked by Wall St. Rank hold ACRS as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Aclaris Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 12,732 Aclaris Therapeutics shares in Q4 2017, an estimated $329K.
  • Nationwide Fund Advisors first reported a position in Aclaris Therapeutics in Q4 2015 and held it in 8 quarters.
  • Nationwide Fund Advisors's Aclaris Therapeutics position peaked at $329K in Q3 2017.
  • 102 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.